Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON26122
NL-OMON26122CompletedNot Applicable

Phase Ib/II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastases.

KI-AV0 sites44 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
44
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

/A

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Changed 8-jun-2015:
  • •1. Adults at least 18 years of age;

Exclusion Criteria

  • •1. Cerebral or meningeal metastasized uveal melanoma;
  • •2. Subjects with any active autoimmune disease or a documented history of
  • •autoimmune disease, or history of syndrome that required systemic steroids or
  • •immunosuppressive medications, except for subjects with vitiligo or resolved
  • •childhood asthma/atopy;

Investigators

Sponsor
KI-AV

Similar Trials

Active, not recruiting
Phase 1
A study to evaluate the safety, the distribution and elimination of the compound in the body, and the effectiveness of Erdafitinib by itself, in combination with JNJ-63723283 (Cetrelimab) or in combination with JNJ- 63723283 (Cetrelimab) and chemotherapy, in patients with metastatic or Locally Advanced urothelial cancer.Metastatic or locally advanced Urothelial CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-001980-19-ITJANSSEN CILAG INTERNATIONAL NV115
Active, not recruiting
Phase 1
A study to evaluate the safety, the distribution and elimination of the compound in the body, and the effectiveness of Erdafitinib by itself, in combination with JNJ-63723283 (Cetrelimab) or in combination with JNJ- 63723283 (Cetrelimab) and chemotherapy, in patients with metastatic or Locally Advanced urothelial cancer.Metastatic or Locally Advanced Urothelial CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-001980-19-GBJanssen-Cilag International NV160
Active, not recruiting
Phase 1
A study to evaluate the safety, the distribution and elimination of thecompound in the body, and the effectiveness of Erdafitinib by itself, in combination with JNJ-63723283 (Cetrelimab) or in combination with JNJ-63723283 (Cetrelimab) and chemotherapy, in patients with metastatic or Locally Advanced urothelial cancer.
EUCTR2017-001980-19-PLJanssen-Cilag International NV160
Recruiting
Phase 2
A study to evaluate the safety, the distribution and elimination of the compound in the body, and the effectiveness of Erdafitinib by itself, in combination with JNJ-63723283 (Cetrelimab) or in combination with JNJ63723283 (Cetrelimab) and chemotherapy, in patients with metastatic or Locally Advanced urothelial cancer.
2023-510295-31-00Janssen Cilag International7
Active, not recruiting
Phase 1
A study to evaluate the safety, the distribution and elimination of the compound in the body, and the effectiveness of Erdafitinib by itself, in combination with JNJ-63723283 (Cetrelimab) or in combination with JNJ63723283 (Cetrelimab) and chemotherapy, in patients with metastatic or Locally Advanced urothelial cancer.
CTIS2023-510295-31-00Janssen Cilag International14